Jin-Zhi Du
Overview
Explore the profile of Jin-Zhi Du including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luo J, Liu R, Chen F, Zhang J, Zheng S, Shao D, et al.
ACS Nano
. 2025 Mar;
19(9):9433.
PMID: 40025817
No abstract available.
2.
Wu C, Liu X, Liu R, Song S, Zheng Z, Zeng Y, et al.
Adv Sci (Weinh)
. 2024 Nov;
12(2):e2407239.
PMID: 39560161
The epidermal growth factor receptor (EGFR) is a validated therapeutic target for RAS/RAF wild-type colorectal cancer (CRC). However, monoclonal antibody-based anti-EGFR therapies such as cetuximab have limited effectiveness. Herein, it...
3.
Tong Q, Huang H, Yu H, Liu R, Shen S, Du J
Biomaterials
. 2024 Oct;
315:122910.
PMID: 39467399
Remodeling the immunosuppressive tumor microenvironment (TME) by immunomodulators has been well studied in the past years. However, strategies that enable concurrent modulation of both the immunosuppressive TME and tumor-draining lymph...
4.
Zhang J, Su Y, Wang X, Yao X, Du J
Wiley Interdiscip Rev Nanomed Nanobiotechnol
. 2024 Oct;
16(5):e2001.
PMID: 39425549
Tumor-associated macrophages (TAMs) constitute the largest number of immune cells in the tumor microenvironment (TME). They play an essential role in promoting tumor progression and metastasis, which makes them a...
5.
Huang H, Tong Q, Chen Y, Liu X, Liu R, Shen S, et al.
J Am Chem Soc
. 2024 Oct;
146(42):29189-29198.
PMID: 39387453
Immunogenic cell death (ICD) has been widely employed to potentiate cancer immunotherapy due to its capability to activate the anticancer immune response. Although various ICD inducers have been described, the...
6.
Li J, Shu N, Zhang Y, Tong Q, Wang L, Zhang J, et al.
ACS Appl Mater Interfaces
. 2024 May;
16(20):25665-25675.
PMID: 38735053
Tumor-associated macrophages (TAMs) usually adopt a tumor-promoting M2-like phenotype, which largely impedes the immune response and therapeutic efficacy of solid tumors. Repolarizing TAMs from M2 to the antitumor M1 phenotype...
7.
Duan Q, Liu R, Luo J, Zhang J, Zhou Y, Zhao J, et al.
Nano Lett
. 2023 Dec;
24(1):402-410.
PMID: 38153842
The ability of drugs to cross the blood-brain barrier (BBB) is crucial for treating central nervous system (CNS) disorders. Inspired by natural viruses, here we report a glucose and polydopamine...
8.
He Y, Cheng C, Liu Y, Chen F, Chen Y, Yang C, et al.
ACS Nano
. 2023 Dec;
18(1):470-482.
PMID: 38146673
Targeted delivery of vaccines to the spleen remains a challenge. Inspired by the erythrophagocytotic process in the spleen, we herein report that intravenous administration of senescent erythrocyte-based vaccines profoundly alters...
9.
Liu R, Liang Q, Luo J, Li Y, Zhang X, Fan K, et al.
Adv Sci (Weinh)
. 2023 Nov;
11(3):e2305217.
PMID: 38029345
Hydrogels are prevailing drug delivery depots to improve antitumor efficacy and reduce systemic toxicity. However, the application of conventional free drug-loaded hydrogel is hindered by poor drug penetration in solid...
10.
Zheng S, Yang M, Luo J, Liu R, Song J, Chen Y, et al.
ACS Nano
. 2023 Aug;
17(16):15905-15917.
PMID: 37565626
Metal-organic frameworks (MOFs) show tremendous promise for drug delivery due to their structural and functional versatility. However, MOFs are usually used as biologically inert carriers in most cases. The creation...